A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors

Mechanisms of resistance to EGFR targeted therapies

(2013) Gorjan Hrustanovic et al.   CANCER BIOLOGY & THERAPY

Pharmacokinetics of Afatinib, a Selective Irreversible ErbB Family Blocker, in Patients with Advanced Solid Tumours

(2013) Sven Wind et al.   CLINICAL PHARMACOKINETICS

Pemetrexed for the treatment of non-small cell lung cancer

(2013) Carlo Genova et al.   EXPERT OPINION ON PHARMACOTHERAPY

Dermatologic adverse events associated with afatinib: an oral ErbB family blocker

(2013) Mario E Lacouture et al.   Expert Review of Anticancer Therapy

Diarrhea associated with afatinib: an oral ErbB family blocker

(2013) James Chih-Hsin Yang et al.   Expert Review of Anticancer Therapy

Dose Reduction or Intermittent Administration of Erlotinib: Which Is Better for Patients Suffering from Intolerable Toxicities?

(2013) Akito Hata et al.   INTERNAL MEDICINE

LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both

(2013) Nobuyuki Katakami et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations

(2013) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

Chemotherapy With Erlotinib or Chemotherapy Alone in Advanced Non-Small Cell Lung Cancer With Acquired Resistance to EGFR Tyrosine Kinase Inhibitors

(2013) S. B. Goldberg et al.   ONCOLOGIST

Prospective Assessment of Continuation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Pemetrexed

(2012) Naruo Yoshimura et al.   Journal of Thoracic Oncology

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

(2012) Vincent A Miller et al.   LANCET ONCOLOGY

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial

(2012) James Chih-Hsin Yang et al.   LANCET ONCOLOGY

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells

(2011) N Ioannou et al.   BRITISH JOURNAL OF CANCER

Intercalated Erlotinib-Docetaxel Dosing Schedules Designed to Achieve Pharmacodynamic Separation: Results of a Phase I/II Trial

(2011) Randeep Sangha et al.   Journal of Thoracic Oncology

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors

(2010) Timothy A. Yap et al.   JOURNAL OF CLINICAL ONCOLOGY

Enhanced Anticancer Effect of the Combination of BIBW2992 and Thymidylate Synthase-Targeted Agents in Non-Small Cell Lung Cancer with the T790M Mutation of Epidermal Growth Factor Receptor

(2010) K. Takezawa et al.   MOLECULAR CANCER THERAPEUTICS

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

(2009) Tudor Ciuleanu et al.   LANCET

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors

(2008) Kwok-Kin Wong   LUNG CANCER

Molecular Mechanisms Underlying the Synergistic Interaction of Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, with the Multitargeted Antifolate Pemetrexed in Non-Small-Cell Lung Cancer Cells

(2008) E. Giovannetti et al.   MOLECULAR PHARMACOLOGY

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

(2008) D Li et al.   ONCOGENE